Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872561 | 1.00 | GBA1 (0.39) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL18526641 | 0.95 | GBA1 (0.39) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL24842356 | 0.93 | GBA1 (0.38) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL23747275 | 0.87 | GBA1 (0.35) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL24773751 | 0.84 | GBA1 (0.45) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL23765241 | 0.82 | GUSB (0.55) | GBA1SIGMAR1GLB1 | |
| SCHEMBL5545683 | 0.82 | HTR7 (0.45) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL25610535 | 0.82 | GBA1 (0.41) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL23896961 | 0.82 | DRD2 (0.33) | GBA1DRD2DRD1DRD4DRD5 | |
| SCHEMBL24818999 | 0.81 | HTR7 (0.44) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-2796460-B1 | PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICINAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017063564-A1 | OCTAHYDROCYCLOPENTA[C]PYRROLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE | 四川海思科制药有限公司 | 2017-04-20 | — | — | WO | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | GBA1 2013/4885DRD2 4008/4885DRD1 3667/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | GBA1 2013/4885DRD2 4008/4885DRD1 3667/4885 |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | GBA1 1560/4885DRD2 3513/4885DRD1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.